Authors
Alejandro Pérez Fidalgo, Ignace Vergote, Erika Hamilton, Giorgio Valabrega, Toon Van Gorp, Jalid Sehouli, Jaroslav Klat, Tally Levy, Stephen Welch, Debra L Richardson, Eva Maria Guerra Alía, Giovanni Scambia, Stéphanie Henry, Pauline Wimberger, David Miller, Jerónimo Martínez, Bradley J Monk, Pratheek Kalyanapu, Mansoor Raza Mirza, Vicky Makker
Publication date
2023/9/1
Source
International Journal of Gynecologic Cancer
Volume
33
Issue
Suppl 3
Publisher
BMJ Specialist Journals
Description
Introduction/Background
Molecular characterization is important to inform treatment decisions for patients with endometrial cancer (EC). Wild type TP53 (TP53wt) is found in ~75% of newly diagnosed EC and 50% of advanced/recurrent tumors; there are no specific targeted therapies for patients with TP53wt EC. Selinexor is an investigational oral XPO1 inhibitor that drives nuclear retention and functional activation of wt tumor suppressor proteins, including p53.
Methodology
SIENDO (NCT03555422) was a phase 3 double-blind study evaluating selinexor vs placebo as maintenance in patients with advanced/recurrent EC. The primary endpoint was progression-free survival (PFS) and first presented at the ESMO plenary in March 2022. Selinexor efficacy and safety was now further assessed with long-term follow-up in a prespecified subgroup of patients with TP53wt EC.
Results
113 patients with TP53wt EC were …
Scholar articles
AP Fidalgo, I Vergote, E Hamilton, G Valabrega… - 2023